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Abstract
The completion of the human genome sequence has led to a rapid increase in genetic information.
The invention of DNA microarrays, which allow for the parallel measurement of thousands of
genes on the level of mRNA, has enabled scientists to take a more global view of biological systems.
Protein microarrays have a big potential to increase the throughput of proteomic research.
Microarrays of antibodies can simultaneously measure the concentration of a multitude of target
proteins in a very short period of time. The ability of protein microarrays to increase the quantity
of data points in small biological samples on the protein level will have a major impact on basic
biological research as well as on the discovery of new drug targets and diagnostic markers. This
review highlights the current status of protein expression profiling arrays, their development,
applications and limitations.
Introduction
The analysis of the entire set of proteins of a biological sys-
tem, commonly called proteomics, represents a research
area that has emerged in the past decade as a largely tech-
nology-driven field [1–4]. Techniques like mass spectrom-
etry in combination with separation tools such as two-
dimensional gel electrophoresis or multidimensional liq-
uid chromatography, allow for the parallel analysis of
abundances of dozens to hundreds of proteins [5–7].
These techniques, however, are very labor intensive and
require a significant amount of biological material. In par-
ticular, two-dimensional gel electrophoresis lacks the sen-
sitivity to detect low abundance proteins.
These disadvantages of existing proteomics technologies
have driven the development of novel miniaturized tools
for the investigation of proteomes. An emerging technol-
ogy in this field is the protein microarray [8–12]. Depend-
ing on the configuration, these arrays can measure protein
expression levels, protein-protein interactions, protein-
small molecule interactions as well as enzymatic activities.
Protein expression profiling arrays are the most advanced
in their development and therefore the major focus of this
review.
The concept of protein expression profiling arrays was
inspired by DNA microarrays, which enable the measure-
ment of mRNA expression level of thousands of genes in
a single experiment [13]. DNA microarrays have proven to
be very powerful tools for the multiplexed comparative
analysis of gene expression and led to important insights
into gene expression patterns associated with disease
states [14–20]. The possibility of performing similar anal-
yses at the level of proteins – the functional products of
almost all genes – is therefore very attractive.
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There are, however, several reasons why DNA microarray
technology cannot readily be adapted towards the devel-
opment of protein microarrays. First, design and synthesis
of gene-specific capture probes is straightforward since it
is based on simple base-pairing rules and standard solid
phase phosphoramidite chemistry, respectively. In con-
trast, the development of capture agents for protein arrays
is far more complicated and requires significantly more
time for development. Currently the preferred capture
agents for protein expression profiling arrays are antibod-
ies or antibody fragments, which have a very long and
costly development time (see below). Furthermore pro-
tein expression levels span a huge range (up to 8 orders of
magnitude). To avoid multiple measurements of the same
sample at different dilutions, protein capture agents with
different affinities have to be developed to address such
dramatic differences in expression level.
Second, an appropriate surface attachment strategy has to
be implemented to immobilize the protein capture agents
onto the array while retaining their binding activity. Fur-
thermore, during the dispensing and immobilization
process, the proteins must remain hydrated to assure the
integrity of their three-dimensional structures, an issue
not relevant to the production of DNA arrays.
Third, especially for high density protein expression pro-
filing arrays, novel detection schemes with adequate sen-
sitivity are required to monitor the specific binding of
proteins by the immobilized capture reagents on the
microarray.
This review will summarize these issues and how they are
addressed. Despite these limitations, impressive advances
have been made towards the development of protein
expression profiling arrays and several publications have
been appeared over the last years showing the use and
power of this technology.
Assay formats
The simplest protein array format consists of a large
number of protein capture reagents bound to defined
spots on a planar support material. This array is then
exposed to a complex protein sample. The binding of the
specific analyte proteins to the individual spots can then
be monitored using different approaches (Figure 1). In
cases where the analytes have been pre-labeled with a flu-
orescent dye, the binding can be monitored directly using
a fluorescence scanner. A major limitation of this assay
configuration lies in the often disappointing sensitivity,
which prohibits the measurement of low abundance pro-
teins. More often, however, the classical antibody sand-
wich type format is used, in which two protein binding
reagents simultaneously bind to the same antigen: one
antibody is immobilized onto the surface, and the other
one is fluorescently labeled or conjugated to an enzyme
that can produce a fluorescent, luminescent or colored
product when supplied with the appropriate substrate.
The disadvantage of this sandwich assay format lies in the
fact that two highly specific protein capture agents must
be developed. The assay itself, however, is more reliable
because direct sample labeling, which is not very consist-
ent between samples, is not required. Furthermore this
assay setup has been successfully used to monitor protein
expression levels at physiologically relevant concentra-
tions [21–23].
Capture agents for protein profiling microarrays
Current estimations assume that the human genome
encodes about 30,000 – 40,000 genes. Due to splice vari-
ants on the mRNA level and a variety of post-translational
modifications, the number of functionally distinct pro-
teins is significantly higher, probably approaching one
million. The development of protein microarrays for
highly multiplexed protein profiling, similar to the multi-
plexing capabilities of DNA microarrays, would therefore
require a large number of capture agents. The develop-
ment of these capture agents is currently the most chal-
lenging bottleneck in protein microarray research.
Monoclonal antibodies or their antigen-binding frag-
ments are currently the preferred choice for capture agents
due to their high specificity, affinity and stability. They
have been used in a variety of classical single analyte pro-
tein profiling assays such as enzyme-linked immunosorb-
ent assays (ELISA) since the seventies. The long
development times and labor-intensive nature of the
process is, however, a major disadvantage [24,25].
To overcome this problem, different 'display' methods are
currently being used and industrialized for the high-
throughput development of protein capture agents.
Phage-display libraries of antibody fragments offer the
potential for antibody production at proteomic scales.
These libraries can be used to isolate high-affinity binding
agents against protein targets in a significantly shorter
time frame than it is possible with immunization-based
methods [26–30]. Furthermore, such methods can be
used to create binding agents against proteins that are
toxic, highly conserved or murine in origin, which are
problematic for tradition mouse monoclonal antibody
generation.
In order to measure picomolar concentrations of proteins,
protein-binding reagents with nanomolar or sub-
nanomolar affinities must be developed. Monoclonal
antibodies can usually reach affinities with dissociation
constants (Kd) in the lower nanomolar to picomolar range
and are therefore suited for protein chip applications. The
size of naïve phage display libraries is the key feature forProteome Science 2003, 1 http://www.Proteomesci.com/content/1/1/3
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the successful isolation of high affinity capture agents.
Only very complex libraries with many billions of individ-
ual clones are suited for the isolation of high quality bind-
ing reagents. Several companies have developed highly
complex libraries over the last years including Dyax, Cam-
bridge Antibody Technology and Morphosys. The con-
struction of high complexity phage libraries does,
however, require a great deal of labor and is limited by the
transformation efficiency of bacteria.
Due to the fact that the size of capture agent libraries is
one of the major limitations for the development of high-
affinity binding agents, additional in vitro evolution meth-
ods have emerged that circumvent the size-limitation of
phage libraries. Ribosome display and mRNA display are
completely in vitro methods that rely on physically linking
the library proteins to their encoding mRNA sequences.
Such methods have successfully been used to select high-
affinity binding reagents to target proteins [31].
These library-based methods provide capture agents based
on antibody fragments or other protein scaffolds. One
inherent limitation of protein-based capture agents is
their lack of stability during array dispensing processes
and subsequent array storage. Several groups have there-
fore taken a completely different approach to develop
Figure 1
Basic principle of a protein expression profiling array and different detection schemes. (A) Capture agents with different ana-
lyte specificity are immobilized on a surface. (B) Incubation with protein samples leads to specific capture of target proteins in 
a concentration dependent manner. (C) After washing, the specifically bound target protein can be visualized by a variety of 
detection schemes, such as (1) direct fluorescence labeling of the analyte with a fluorophore (F) (labeled prior to the experi-
ment), (2) detection of the target protein by a fluorescently-labeled detection antibody or (3) an enzyme-conjugated detection 
antibody, allowing an ELISA-based detection with a fluorescent, chemiluminescent or colorimetric readout (S = substrate, P = 
product).
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high affinity protein capture reagents for protein biochips.
Aptamers are single stranded RNA or DNA molecules orig-
inating from in vitro selection experiments (termed SELEX:
systematic evolution of ligands by exponential enrich-
ment) with high affinities to proteins [32,33]. Aptamers
against a number of proteins have been successfully
selected from libraries with a complexity of over 1014 mol-
ecules (for review see [34]). A further development in
aptamer technologies are so called photoaptamers. These
molecules have an additional attribute that enhances their
utility as protein capture reagents. They carry the photoac-
tivatible crosslinking group 5'-bromodeoxyuridine,
which, when activated by UV light, can cause covalent
crosslinking with bound target proteins [35]. The photo-
crosslinking event provides a second dimension of specif-
icity similar to the binding of a secondary detection anti-
body in a sandwich immunoassay. In a study by Golden
et al. photoaptamers were used to crosslink low picomo-
lar concentrations of fibroblast growth factor, in the pres-
ence of serum, with very high specificity [36].
Regardless of the type of capture agent, high specificity
and affinity are crucial. Due to the multiplexed nature of
microarray assays, high specificity is absolutely required
to avoid cross-reactivity. Extensive cross-reactivity scans
between binding agents to be used together on a microar-
ray must be performed as part of the screening process to
identify suitable reagents. Another important criterion is
the affinity of the capture agents. Protein microarrays are
especially attractive for protein expression profiling of low
abundance proteins that cannot be visualized by 2D-
PAGE techniques. The capture agents should have affini-
ties not more than 2 orders of magnitude higher than the
biological concentrations of the target proteins for reliable
detection. Since some important proteins are present at
low picomolar concentrations in serum, for example,
antibodies with sub-nanomolar affinities should be used.
In order to create these protein capture reagents, a target
protein must be synthesized and purified. Several groups
have started to develop methods for rapid parallel expres-
sion and purification of proteins. The most widely used
system is based on expression in E. coli, but a large
number of human proteins expressed in this system are
misfolded and insoluble. These misfolded proteins are
often not useful for the development of antibodies that
recognize the native form of a protein with high affinity.
The refolding of proteins from inclusion bodies is difficult
to perform in high throughput. For most human proteins,
it will therefore be therefore necessary to access alternative
expression systems that rely on mammalian or insect cells.
Automation of some of these eukaryotic expression sys-
tems is currently being explored [37].
Immobilization of capture agents for protein microarrays: 
where chemistry meets biology
The nature of the surface substrate and attachment strat-
egy is one of the major factors for determining the quality
of data obtained during protein microarray experiments.
For optimal sensitivity and reproducibility, the activity of
the immobilized capture agent has to be retained and
non-specific binding of proteins to the surface must be
minimized.
A wide variety of surface substrates and attachment chem-
istries have been evaluated for the immobilization of cap-
ture agents on protein microarrays. They fall into two
basic categories. The simplest way to immobilize proteins
on a solid support relies on non-covalent interactions.
These immobilizations can be either based on hydropho-
bic or van der Waals interactions, hydrogen bonding or
electrostatic forces. Examples of electrostatic immobiliza-
tion include the use of materials such as nitrocellulose
and poly-lysine- or aminopropyl silane-coated glass slides
[38]. Protein microarrays were also fabricated by means of
physical adsorption onto plastic surfaces of 96-well plates
[21]. A big advantage of these immobilization concepts is
their ease of use. Usually no protein modification is
needed prior to printing onto the surface. The disadvan-
tage is that proteins often get denatured on these fairly
undefined surfaces due multiple uncontrolled interac-
tions between the protein and the surface material.
Physical adsorption of proteins onto surfaces can also
lead to problems with protein desorption during the
assay, which can lead to signal loss. It is therefore more
desirable to attach the protein capture molecule cova-
lently and in a controlled way onto the surface. An exam-
ple of covalent attachment of proteins to the surface has
been described by MacBeath and Schreiber [39]. However
in this case the immobilization was random, which can
lead to a decreased sensitivity compared to an oriented
immobilization. In the ideal setup, a single covalent bond
would mediate the attachment. Due to the very high affin-
ity of streptavidin to biotin, the immobilization of bioti-
nylated proteins onto streptavidin surfaces can be
considered quasi covalent. Using this strategy, Peluso et
al. [40] were able to demonstrate that an oriented single
site attachment of an antibody fragment leads to an
increase in sensitivity over random attachment in a micro-
array assay.
The fact that a variety of different surface substrates have
been used with success might indicate that the immobili-
zation strategy is not the most critical parameter in the
production of protein microarrays. The data quality with
respect to parameters like signal-to-noise ratio and repro-
ducibility, however, is influenced by the attachment strat-
egy and processing of the arrays. Different surfaceProteome Science 2003, 1 http://www.Proteomesci.com/content/1/1/3
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substrates, for example, require different blocking strate-
gies to gain optimal data quality. MacBeath and Schreiber
used BSA-coated slides to reduce non-specific binding
[39]. A more sophisticated approach was taken by Ruiz-
Taylor et al. [41,42]. They engineered surfaces to avoid
non-specific protein adsorption using poly (ethylene gly-
col) derivates as coatings. Protein microarrays based on
this method of attachment of capture molecules onto oth-
erwise protein-resistant surfaces have shown to be of very
high quality [40].
Detection strategies for multiplexed protein microarray 
applications
The preferred method for detecting binding events on a
protein microarray relies on fluorescence. As described
above, there are two ways to incorporate fluorophores
into an assay: (1) direct fluorescent labeling of the protein
sample, and (2) sandwich immunoassays with labeled
detection antibodies. The use of a miniaturized sandwich
assay also allows for incorporation of enzymes which
then can be used for signal amplification. For example
Huang [43] has shown the simultaneous detection of dif-
ferent cytokines from conditioned media and patient sera
using an array-based enzyme-linked immunosorbent
assay in combination with enhanced chemiluminescence
(ECL).
The choice of the detection strategy is partially determined
by the application. A direct labeling of the protein sample
can be applied to the analysis of cell lysates or purified
protein samples. Miller et al. used a direct Cy3/Cy5 labe-
ling strategy to perform differential profiling of prostate
cancer biomarkers in serum samples [44]. They were able
to identify five proteins that had significantly different
expression levels between prostate cancer samples and
normal controls. For quantitative studies with a limited
number of specificities on a chip, however, a sandwich
immunoassay format is preferred. Medium density arrays
of antibodies against cytokines and other medically
important proteins have been developed [21–23,45].
The fact that multiplexed protein microarray assays are
performed on a flat surface adds certain restrictions to an
ELISA-based assay setup. The resulting enzyme product
must be either an insoluble precipitate or attached to a
certain component of the microarray spot. Wiese et al.
[23] performed a cytokine profiling microarray assay with
an alkaline phosphatase-conjugated detection antibody,
which generated a fluorescent precipitate. Another highly
sensitive ELISA-based detection strategy has been
described which uses rolling circle amplification (RCA) as
a detection strategy [46,47]. This on-chip signal amplifica-
tion strategy was used to perform very sensitive assays for
highly multiplexed cytokine profiling and detection of
allergen-specific IgE's in serum samples [48,49]. Further
improvement in sensitivity involves the application of flu-
orescent labels in combination with waveguide technol-
ogy. Rowe-Taitt et al. [50] have applied this technology to
detect clinical analytes and biohazardous agents in com-
plex samples at physiologically relevant concentrations.
Thin film waveguides generated from a high-refractive
material such as Ta2O5 have been successfully used by
Duveneck et al. [51].
Protein microarrays: Beyond protein profiling
Although the major use of protein microarrays is currently
in the field of expression profiling, several applications of
functional arrays and protein-protein interaction arrays
have been described. Zhu et al. [52] cloned and arrayed
into nanowells 119 protein kinases from yeast. They then
assayed their activity using 17 different substrates in the
presence of radiolabeled ATP. Following the incorpora-
tion of radioactive phosphate, they were able to identify
the substrate preferences of most of these kinases. The
same later undertook the heroic effort to clone and
express nearly all of the 5,800 yeast open reading frames
[53]. An array of these yeast proteins was created and
probed for binding to calmodulin and certain lipids. They
were able to identify 6 known calmodulin-binding pro-
teins and several lipid-binding proteins. Once this
approach is transferred to human proteins, a variety of
novel protein-protein as well as protein-small molecule
interactions will be discovered.
Another emerging microarray format consists of peptide
arrays for the profiling of protein activity. An array of pep-
tides on a gold surface was developed to monitor c-Src
kinase activity. Phosphorylation of the immobilized pep-
tide substrates was shown using radioactivity, fluores-
cence or surface plasmon resonance as detection [54].
Another group has demonstrated the use of fluorescently
labeled phospho-specific antibodies to detect the phos-
phorylation event on immobilized peptide substrates
[55].
Small-molecule microarrays have also been developed to
detect the binding of proteins to an array of immobilized
compounds [56,57]. These new microarray platforms will
prove invaluable to basic biological research and have the
potential to accelerate the pace of discovery of drug targets
as well as lead compounds.
Conclusions
Since the initial conception of microspot assays [58], a
variety of advances have been demonstrated for this plat-
form to improve the multiplexing capabilities, reproduci-
bility and sensitivity. In particular, the ongoing
development of new techniques for the high-throughput
production of protein capture reagents represents a key to
the success of multiplexed protein microarrays assays.Proteome Science 2003, 1 http://www.Proteomesci.com/content/1/1/3
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This technology platform, however, is still not at a stage
where it could be compared with the commercial success
of DNA microarrays. A few companies, such as Zyomyx,
Ciphergen Pierce, Zeptosens, and BD Clontech have com-
mercialized protein microarrays, but their applicability
and competitive advantage over other, more macroscopic
protein profiling platforms still needs to be proven.
Acknowledgement
We would like to thank David Wilson for the critical reading of the 
manuscript.
References
1. Patterson SD and Aebersold RH: Proteomics: the first decade
and beyond Nat Genet 2003, 33 Suppl:311-323.
2. Chambers G, Lawrie L, Cash P and Murray GI: Proteomics: a new
approach to the study of disease J Pathol 2000, 192:280-288.
3. Dutt MJ and Lee KH: Proteomic analysis Curr Opin Biotechnol 2000,
11:176-179.
4. Pandey A and Mann M: Proteomics to study genes and genomes
Nature 2000, 405:837-846.
5. Aebersold R and Mann M: Mass spectrometry-based
proteomics Nature 2003, 422:198-207.
6. Washburn MP, Wolters D and Yates JR,III: Large-scale analysis of
the yeast proteome by multidimensional protein identifica-
tion technology Nat Biotechnol 2001, 19:242-247.
7. Wolters DA, Washburn MP and Yates JR,III: An automated multi-
dimensional protein identification technology for shotgun
proteomics Anal Chem 2001, 73:5683-5690.
8. Zhu H and Snyder M: Protein arrays and microarrays Curr Opin
Chem Biol 2001, 5:40-45.
9. Kodadek T: Protein microarrays: prospects and problems
Chem Biol 2001, 8:105-15.
10. Templin MF, Stoll D, Schrenk M, Traub PC, Vohringer CF and Joos
TO:  Protein microarray technology  Trends Biotechnol 2002,
20:160-166.
11. Wilson DS and Nock S: Recent developments in protein micro-
array technology Angew Chem Int Ed Engl 2003, 42:494-500.
12. Wilson DS and Nock S: Functional Protein Microarrays Curr Opin
Chem Biol 2002, 6:81-85.
13. Schena M, Shalon D, Davis RW and Brown PO: Quantitative mon-
itoring of gene expression patterns with a complementary
DNA microarray Science 1995, 270:467-470.
14. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov
JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD and
Lander ES: Molecular Classification of Cancer: Class Discovery
and Class Prediction by Gene Expression Monitoring Science
1999, 286:531-537.
15. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A,
Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore
T, Hudson J.,Jr., Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC,
Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Staudt LM
and .: Distinct types of diffuse large B-cell lymphoma identi-
fied by gene expression profiling Nature 2000, 403:503-511.
16. Perou CM, Sorlie T, Eisen MB, van de Rijn M., Jeffrey SS, Rees CA, Pol-
lack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A,
Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO and
Botstein D: Molecular portraits of human breast tumours
Nature 2000, 406:747-752.
17. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie
T, Eisen MB, van de Rijn M., Jeffrey SS, Thorsen T, Quist H, Matese
JC, Brown PO, Botstein D, Eystein Lonning P. and Borresen-Dale AL:
Gene expression patterns of breast carcinomas distinguish
tumor subclasses with clinical implications Proc Natl Acad Sci
2001, 98:10869-10874.
18. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kura-
chi K, Pienta KJ, Rubin MA and Chinnaiyan AM: Delineation of
prognostic biomarkers in prostate cancer  Nature 2001,
412:822-826.
19. Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O'Connell JX,
Zhu S, Fero M, Sherlock G, Pollack JR, Brown PO, Botstein D and van
de Rijn M.: Molecular characterisation of soft tissue tumours:
a gene expression study Lancet 2002, 359:1301-1307.
20. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M,
McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC,
Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T,
Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov
JP, Lander ES and Golub TR: Prediction of central nervous
system embryonal tumour outcome based on gene
expression Nature 2002, 415:436-442.
21. Moody MD, Van Ardel SW, Orencole SF and Burns C: Array-based
ELISAs for high-throughput analysis of human cytokines Bio-
techniques 2001, 31:186-194.
22. Mendoza LG, McQuary P, Mongan A, Gangadharan R, Brignac S and
Eggers M: High-throughput microarray-based enzyme-linked
immunosorbent assay (ELISA) Biotechniques 1999, 27:778-788.
23. Wiese R, Belosludtsev Y, Powdrill T, Thompson P and Hogan M:
Simultaneous multianalyte ELISA performed on a microar-
ray platform Clin Chem 2001, 47:1451-1457.
24. Liddell JE and Cryer A: A practical guide to monoclonal antibodies Chich-
ester, John Wiley & Sons; 1991.
25. Goding JW: Monoclonal Antibodies: Principles and Practice 3rdth edition.
San Diego, Academic Press; 1996.
26. Sheets MD, Amersdorfer P, Finnern R, Sargent P, Lindquist E, Schier
R, Hemingsen G, Wong C, Gerhart JC, Marks JD and Lindqvist E: Effi-
cient construction of a large nonimmune phage antibody
library: the production of high-affinity human single-chain
antibodies to protein antigens [published erratum appears
in Proc Natl Acad Sci U S A 1999 Jan 19;96(2):795] Proc Natl
Acad Sci U S A 1998, 95:6157-6162.
27. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Hen-
derikx P, de Bru, Arends JW and Hoogenboom HR: A Large Non-
immunized Human Fab Fragment Phage Library That Per-
mits Rapid Isolation and Kinetic Analysis of High Affinity
Antibodies J Biol Chem 1999, 274:18218-18230.
28. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G,
Hoess A, Wolle J, Pluckthun A and Virnekas B: Fully synthetic
human combinatorial antibody libraries (HuCAL) based on
modular consensus frameworks and CDRs randomized with
trinucleotides J Mol Biol 2000, 296:57-86.
29. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earn-
shaw JC, McCafferty J, Hodits RA, Wilton J and Johnson KS: Human
antibodies with sub-nanomolar affinities isolated from a
large non-immunized phage display library Nat Biotechnol 1996,
14:309-314.
30. Wittrup KD: Protein engineering by cell-surface display Curr
Opin Biotechnol 2001, 12:395-399.
31. Wilson DS, Keefe AD and Szostak JW: The use of mRNA display
to select high-affinity protein-binding peptides Proc Natl Acad
Sci U S A 2001, 98:3750-3755.
32. Brody EN and Gold L: Aptamers as therapeutic and diagnostic
agents J Biotechnol 2000, 74:5-13.
33. Robertson MP and Ellington AD: In vitro selection of nucleopro-
tein enzymes Nat Biotechnol 2001, 19:650-655.
34. Jayasena SD: Aptamers: an emerging class of molecules that
rival antibodies in diagnostics Clin Chem 1999, 45:1628-1650.
35. Petach H and Gold L: Dimensionality is the issue: use of pho-
toaptamers in protein microarrays Curr Opin Biotechnol 2002,
13:309-314.
36. Golden MC, Collins BD, Willis MC and Koch TH: Diagnostic
potential of PhotoSELEX-evolved ssDNA aptamers  J
Biotechnol 2000, 81:167-178.
37. Gilbert M and Albala JS: Accelerating code to function: sizing up
the protein production line Curr Opin Chem Biol 2002, 6:102-105.
38. Haab BB, Dunham MJ and Brown PO: Protein microarrays for
highly parallel detection and quantitation of specific proteins
and antibodies in complex solutions  Genome Biol 2001,
2:RESEARCH0004.
39. MacBeath G and Schreiber SL: Printing proteins as microarrays
for high-throughput function determination  Science 2000,
289:1760-1763.
40. Peluso P, Wilson DS, Do D, Tran H, Venkatasubbaiah M, Quincy D,
Heidecker B, Poindexter K, Tolani N, Phelan M, Witte K, Jung LS,
Wagner P and Nock S: Optimizing antibody immobilization
strategies for the construction of protein microarrays Anal
Biochem 2003, 312:113-124.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Proteome Science 2003, 1 http://www.Proteomesci.com/content/1/1/3
Page 7 of 7
(page number not for citation purposes)
41. Ruiz-Taylor LA, Martin TL and Wagner P: X-ray photoelectron
spectroscopy and radiometry studies of biotin-derivatized
poly(L-lysine)-grafted-poly(ethylene glycol) monolayers on
metal oxides Volume 17. Langmuir; 20017313-7322.
42. Ruiz-Taylor LA, Martin TL, Zaugg FG, Witte K, Indermuhle P, Nock
S and Wagner P: Monolayers of derivatized poly(L-lysine)-
grafted poly(ethylene glycol) on metal oxides as a class of
biomolecular interfaces Proc Natl Acad Sci U S A 2001, 98:852-857.
43. Huang RP: Simultaneous detection of multiple proteins with
an array-based enzyme- linked immunosorbent assay
(ELISA) and enhanced chemiluminescence (ECL) Clin Chem
Lab Med 2001, 39:209-214.
44. Miller JC, Zhou H, Kwekel J, Cavallo R, Burke J, Butler EB, Teh BS and
Haab BB: Antibody microarray profiling of human prostate
cancer sera: Antibody screening and identification of poten-
tial biomarkers Proteomics 2003, 3:56-63.
45. Tam SW, Wiese R, Lee S, Gilmore J and Kumble KD: Simultaneous
analysis of eight human Th1/Th2 cytokines using
microarrays J Immunol Methods 2002, 261:157-165.
46. Lizardi PM, Huang X, Zhu Z, Bray-Ward P, Thomas DC and Ward
DC: Mutation detection and single-molecule counting using
isothermal rolling-circle amplification Nat Genet 1998, 19:225-
232.
47. Schweitzer B, Wiltshire S, Lambert J, O'Malley S, Kukanskis K, Zhu Z,
Kingsmore SF, Lizardi PM and Ward DC: Immunoassays with roll-
ing circle DNA amplification: a versatile platform for ultra-
sensitive antigen detection  Proc Natl Acad Sci U S A 2000,
97:10113-10119.
48. Schweitzer B, Roberts S, Grimwade B, Shao W, Wang M, Fu Q, Shu
Q, Laroche I, Zhou Z, Tchernev VT, Christiansen J, Velleca M and
Kingsmore SF: Multiplexed protein profiling on microarrays by
rolling-circle amplification Nat Biotechnol 2002, 20:359-365.
49. Wiltshire S, O'Malley S, Lambert J, Kukanskis K, Edgar D, Kingsmore
SF and Schweitzer B: Detection of multiple allergen-specific
IgEs on microarrays by immunoassay with rolling circle
amplification Clin Chem 2000, 46:1990-1993.
50. Rowe-Taitt CA, Hazzard JW, Hoffmann KE, Cras JJ, Golden JP and
Ligler FS: Simultaneous detection of six biohazardous agents
using a planar waveguide array biosensor Biosens Bioelectron
2000, 15:579-589.
51. Duveneck GL, Pawlak M and Neuschaefer D: Novel bioaffinity sen-
sors for trace analysis based on luminescence excitation by
planar waveguides Sens Actuators B 1997, B38:88-95.
52. Zhu H, Klemic JF, Chang S, Bertone P, Casamayor A, Klemic KG,
Smith D, Gerstein M, Reed MA and Snyder M: Analysis of yeast
protein kinases using protein chips Nat Genet 2000, 26:283-289.
53. Zhu H, Bilgin M, Bangham R, Hall D, Casamayor A, Bertone P, Lan N,
Jansen R, Bidlingmaier S, Houfek T, Mitchell T, Miller P, Dean RA,
Gerstein M and Snyder M: Global Analysis of Protein Activities
Using Proteome Chips Science 2001, 293:2101-2105.
54. Houseman BT, Huh JH, Kron SJ and Mrksich M: Peptide chips for
the quantitative evaluation of protein kinase activity  Nat
Biotechnol 2002, 20:270-274.
55. Lesaicherre ML, Uttamchandani M, Chen GY and Yao SQ: Antibody-
based fluorescence detection of kinase activity on a peptide
array Bioorg Med Chem Lett 2002, 12:2085-2088.
56. MacBeath G, Koehler AN and Schreiber SL: Printing small mole-
cules as microarrays and detecting protein-ligand interac-
tions en masse J Am Chem Soc 1999, 121:7967-7968.
57. Kuruvilla FG, Shamji AF, Sternson SM, Hergenrother PJ and Schreiber
SL: Dissecting glucose signalling with diversity-oriented syn-
thesis and small-molecule microarrays Nature 2002, 416:653-
657.
58. Ekins RP and Chu FW: Multianalyte microspot immunoassay--
microanalytical "compact disk" of the future Clin Chem 1991,
37:1955-1967.